Who is sponsoring NCT04975243?

NCT04975243 is sponsored by Candela Corporation.

What drugs are being tested in NCT04975243?

Interventions in NCT04975243: GentleMax Pro Plus 755nm and 1064nm laser system.

What condition does NCT04975243 study?

NCT04975243 studies Unwanted Fine Facial Hair.

Is NCT04975243 still recruiting?

NCT04975243 is currently status unknown. Last updated 9 February 2023.

Last reviewed 2023-02-09 · How we verify

NCT04975243

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro™/GentleMax Pro Plus™

Status unknown NA Last updated 9 February 2023

What this trial tests

NA trial testing GentleMax Pro Plus 755nm and 1064nm laser system in Unwanted Fine Facial Hair in 20 participants. Status unknown.

Timeline

19 March 2021

Primary endpoint
30 November 2022

30 September 2023

Quick facts

Lead sponsor	Candela Corporation
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	19 March 2021
Primary completion	30 November 2022
Estimated completion	30 September 2023
Sites	1 location across United States

Drugs / interventions tested

GentleMax Pro Plus 755nm and 1064nm laser system

Conditions studied

Unwanted Fine Facial Hair — all drugs for Unwanted Fine Facial Hair →

Sponsor

Candela Corporation — full company profile →

Who can join

18 and older, any sex, with Unwanted Fine Facial Hair. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical study is intended to evaluate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended use of hair removal while using short pulse durations to improve the efficacy of achieving permanent reduction of fine facial hairs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Candela Corporation trials

Trials by the same sponsor.

NCT06219278 — A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles · completed
NCT06202274 — Clinical Study to Evaluate the Safety and Efficacy of Candela Technology · NA · active not recruiting
NCT06157567 — Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System · NA · active not recruiting
NCT04993066 — Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus · NA · completed
NCT06192550 — Functional Usability and Feasibility Testing of the Profound Matrix™ System · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04975243 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Candela Corporation
Last refreshed: 9 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04975243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing